Company news
Sight Sciences, Inc. (NASDAQ:SGHT) news
Sight Sciences, Inc. news releases on 6ix. Latest, Apr 10, 2024: Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating…
Press releases — page 2
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications a...
April 9, 2024
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 1, 2024
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
March 6, 2024
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
February 21, 2024
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
February 13, 2024
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
January 22, 2024
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
January 7, 2024
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
December 27, 2023
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
December 17, 2023
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
December 7, 2023
Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023
November 6, 2023
Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
October 23, 2023
Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
October 18, 2023
Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting
October 11, 2023
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
October 2, 2023
Sight Sciences Appoints Matt Link as Chief Commercial Officer
September 10, 2023
Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
August 2, 2023
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
July 19, 2023
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
July 19, 2023
Sight Sciences Announces Addition of New Director Catherine Mazzacco
June 8, 2023
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical S...
May 22, 2023
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
May 5, 2023
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
May 3, 2023
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
April 19, 2023
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
April 2, 2023
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
March 12, 2023
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
March 8, 2023
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
February 22, 2023
Sight Sciences Announces 1,000th TearCare® Customer Installation
January 25, 2023
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
January 8, 2023
Sight Sciences Reports Third Quarter 2022 Financial Results
November 9, 2022
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
November 2, 2022
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
October 19, 2022
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
September 28, 2022
Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®
September 12, 2022
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
August 22, 2022
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
August 15, 2022
Sight Sciences Reports Second Quarter 2022 Financial Results
August 10, 2022
Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
July 27, 2022
Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors
July 18, 2022
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
May 30, 2022
Sight Sciences Reports First Quarter 2022 Financial Results
May 9, 2022
Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 19, 2022
Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022
April 13, 2022
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results
March 23, 2022
Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
March 23, 2022
Sight Sciences Announces Appointment of Brenda Becker to Board of Directors
March 15, 2022
Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting
March 1, 2022
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma
February 16, 2022
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results
January 9, 2022